RT Journal Article
SR Electronic
T1 Validation of a rapid, saliva-based, and ultra-sensitive SARS-CoV-2 screening system for a pandemic-scale infection surveillance
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.04.21265951
DO 10.1101/2021.11.04.21265951
A1 Dewhurst, Robert E
A1 Heinrich, Tatjana
A1 Watt, Paul
A1 Ostergaard, Paul
A1 Marimon, Jose Maria
A1 Moreira, Mariana
A1 Houldsworth, Philip E
A1 Rudrum, Jack D
A1 Wood, David
A1 Kõks, Sulev
YR 2022
UL http://medrxiv.org/content/early/2022/02/21/2021.11.04.21265951.abstract
AB Without any realistic prospect of comprehensive global vaccine coverage and lasting immunity, control of pandemics such as COVID-19 will require implementation of large-scale, rapid identification and isolation of infectious individuals to limit further transmission. Here, we describe an automated, high-throughput integrated screening platform, incorporating saliva-based loop-mediated isothermal amplification (LAMP) technology, that is designed for population-scale sensitive detection of infectious carriers of SARS-CoV-2 RNA. Central to this surveillance system is the “Sentinel” testing instrument, which is capable of reporting results within 25 minutes of saliva sample collection with a throughput of up to 3,840 results per hour. It incorporates continuous flow loading of samples at random intervals to cost-effectively adjust for fluctuations in testing demand. Independent validation of our saliva-based RT-LAMP technology on an automated LAMP instrument coined the “Sentinel”, found 98.7% sensitivity, 97.6% specificity, and 98% efficiency against a RT-PCR comparator assay, confirming its suitability for surveillance screening. This Sentinel surveillance system offers a feasible and scalable approach to complement vaccination, to curb the spread of COVID-19 variants, and control future pandemics to save lives.One-Sentence Summary Development of a high-throughput LAMP-based automated continuous flow, random access SARS-CoV-2 screening platform with sufficient sensitivity and specificity to enable pandemic-scale population testing of infectious individuals using saliva sampling.Competing Interest StatementPW and PO are founders of Avicena Systems, SK is founder of the Prion.Funding StatementDevelopment of the Avicena Sentinel Instrument was supported by grants from the Department of Health, Western Australia, Department of Premier and Cabinet of Western Australia, Western Australian Department of Jobs, Tourism, Science and Industry, and a federal grant Modern Manufacturing Initiative grant from the Department of Industry, Science, Energy and Resources, Australian Government. SK was supported by the Perron Institute for Neurological and Translational Science, Perth, WA.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Sir Charles Gairdner and Osborne Park Health Care Group Human Research Ethics Committee gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors